Ranbaxy-GSK to develop respiratory drug.
Economic Times (New Delhi, India), April, 2007
Apr. 4--NEW DELHI -- Ranbaxy will develop a respiratory inflammation drug in collaboration GlaxoSmithKline (GSK), as part of their new multi-year R&D agreement, a Ranbaxy release on Monday said. Ranbaxy could get up to $100 million in potential milestone payments for a product developed by it and subsequently launched by GSK in multiple indications.
In addition, Ranbaxy stands to get double-digit royalties on worldwide sales of the drug, Ranbaxy said. The research programme will focus on chronic obstructive pulmonary disease (COPD).
As per the agreement between Ranbaxy's New Drug Discovery Research (NDDR) and GSK's Center of Excellence for External Drug Discovery (CEEDD), Ranbaxy will profile the drug candidate through pre clinical studies to support...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
